行情

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

1.400
+0.330
+30.84%
已收盘, 19:54 12/09 EST
开盘
1.080
昨收
1.070
最高
1.450
最低
1.080
成交量
257.44万
成交额
--
52周最高
10.44
52周最低
0.7200
市值
3,772.99万
市盈率(TTM)
-0.2268
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SEEL 新闻

  • Seelos nabs U.S. patent for SLS-005; shares up 8% premarket
  • seekingalpha.5天前
  • Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) 
  • GlobeNewswire.5天前
  • 民主党正酝酿弹劾“大招” 特朗普却到英国去了
  • 新京报网.6天前
  • 趣头条Q3净营收14.07亿元 超市场预期
  • 新浪美股.6天前

更多

所属板块

制药
+0.14%
制药与医学研究
+0.23%

热门股票

名称
价格
涨跌幅

SEEL 简况

Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).
展开

Webull提供Seelos Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。